Personal profile
Professional Information
Treatment Philosophy
I am a medical oncologist specializing in the treatment of genitourinary cancers. As a medical oncologist, I work with patients at all phases of malignant disease, which allows me the opportunity to join patients and families on a journey that can be at times both exhilarating and exhausting. I understand that the patient-oncologist relationship is a unique partnership and one that I take seriously. The journey of cancer provides access to moments in life that can be emotionally challenging for all parties, and I view my role as one ultimately about providing information and guidance to help navigate the path in the way best suited to each patient.
I find genitourinary oncology to be a particularly satisfying and exciting field within medical oncology. It includes a diverse group of patients and a variety of different disease with their own unique opportunities and challenges. It is an area involved in a great deal of research, which has afforded new treatment options for patients, and allows me to be involved in helping patients live longer, live better, and in some instances, even help cure them of their disease.
Fortunately, at Fox Chase Cancer Center, our faculty and staff are dedicated and united towards one goal – optimally treating patients with cancer. I completed my oncology training at Fox Chase and was fortunate to be able to continue as an attending physician at this world-class institution. As part of Fox Chase, our patients have access to the cutting edge of clinical oncology, including the ability to have access to exciting new drugs as part of clinical trials. Medical oncology is a rapidly evolving world, with new treatments and possibilities continually being made available to improve patient outcomes, and Fox Chase strives to remain at the forefront of those changes.
Specialties
- Genitourinary Medical Oncology
Areas of Expertise
Adrenal Tumor, Penile Cancer, Ureteral Cancer, Kidney Cancer, Testicular Cancer, Bladder Cancer, Prostate Cancer, Urethral Cancer
Research interests
- Genitourinary Oncology
- Immune Related Adverse Events
- Immunotherapy
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Assessing Treatment Outcomes of Patients Undergoing Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer
Rives, H., Fredette, J., Anari, F., Ghatalia, P., Geynisman, D., Plimack, E. & Zibelman, M., Mar 3 2026, (E-pub ahead of print) In: Clinical Genitourinary Cancer.Research output: Contribution to journal › Article › peer-review
-
Assessing Treatment Outcomes of Patients Undergoing Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer
Rives, H., Fredette, J., Anari, F., Ghatalia, P., Geynisman, D., Plimack, E. & Zibelman, M., 2026, (Accepted/In press) In: Clinical Genitourinary Cancer. 102525.Research output: Contribution to journal › Article › peer-review
-
Perioperative Immune-Checkpoint Inhibition in Renal Cell Carcinoma: Lessons Learned and Future Directions
Adika, A. & Zibelman, M., Feb 2026, In: Cancers. 18, 3, 527.Research output: Contribution to journal › Review article › peer-review
Open Access -
ALK-rearranged renal cell carcinoma with gains of chromosomes 7 and 17q --- A case report
Chaudhari, M., Yahya, H. A., Pei, J., DiNatale, G. J., Mahan, I., Mark, J. R., Patchefsky, A. S., Zibelman, M. R. & Wei, S., Nov 2025, In: Urology Case Reports. 63, p. 103219 103219.Research output: Contribution to journal › Article › peer-review
Open Access -
Comparison of Outcomes Between African American and European American Patients With Metastatic Clear Cell Renal Cell Carcinoma Receiving Immune Checkpoint Inhibitors
Kaur, J., Hasler, J. S., Handorf, E. A., Zibelman, M. R., Anari, F., Geynisman, D. M. & Ghatalia, P., Apr 2025, In: Clinical Genitourinary Cancer. 23, 2, p. 102304 102304.Research output: Contribution to journal › Article › peer-review
Press/Media
-
Fox Chase Cancer Center: Combined Tests Could Reduce Unnecessary Bladder Removal
02/26/26 → 02/27/26
2 items of Media coverage
Press/Media
-
Piston Bio Received Endorsement from Leading Oncologists for its Tumor Antigen-Inducing Therapeutic
07/17/25
1 item of Media coverage
Press/Media
-
Piston Bio Receives Endorsement from Leading Oncologists for its Tumor Antigen-Inducing Therapeutic
07/15/25
45 items of Media coverage
Press/Media